Anyone can have lupus, but the fact is that women have more than their fair share of this autoimmune condition. In the U.S., an estimated 1 million to 1.5 million people have lupus, and women account for about 90% of lupus diagnoses.
Facial rashes, persistent fatigue and joint pain are more familiar lupus symptoms. However, with systemic lupus erythematosus, the most common and serious form, inflammation flare-ups and symptoms may involve multiple organs including the brain, heart and kidneys.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.